Close menu

March 20th, 2023 | 09:37 CET

Evotec, Defence Therapeutics, Morphosys - Movement in the biotech sector

  • Biotechnology
  • Investments
Photo credits:

Is a new wave of takeovers starting in the biotech sector? Already last year, acquisitions by Big Pharma were expected to increase, but these largely failed to materialize. However, this could accelerate in the current year. On the one hand, pharmaceutical companies, such as vaccine manufacturer Pfizer, have deep pockets and need new innovations for their product portfolio; on the other hand, second-tier stocks are attractive targets due to the strong correction.

time to read: 3 minutes | Author: Stefan Feulner

Table of contents:

    Defence Therapeutics - Entry into a new market

    The positive news continues for the Canadian biotech company, and its patented platform technology is becoming increasingly popular. With the so-called Accum technology, the innovator is working to develop the next generation of vaccines and ADC products. The Accum platform has been developed and tested in vitro and in vivo in animals to optimize intranuclear drug transport in several US FDA-approved antibody-drug conjugates or new conjugates under development.

    The technology allows precise transport of vaccine antigens or ADCs in the intact form to target cells. Based on Accum, Defence Therapeutics has already developed plans around therapeutic vaccines against cancer, a vaccine against infections with the HP virus, which also has potential for acute therapeutic use, and the chemotherapeutic AccuTOX.

    In conjunction with cooperation with the French state-owned group Orano, the Company is now entering the radiopharmaceutical market. Here, the Accum technology will serve as a radionuclide-antibody conjugate. Instead of a drug, a radioactive emitter is moved into the vicinity of the cell nucleus of tumor cells. This is intended to cause the emitter to damage the cancer cell's nucleus to the point of cell death. For a recent update, you can read here.

    Sebastien Plouffe, CEO of Defence Therapeutics, looks forward to the continued progress of Acccum's expanding pipeline and added: "We have a long experience or relevant expertise related to the development and deployment of our AccumTM platform technology, including in the therapeutic use of antibody-drug conjugates, and we strongly believe that Orano, with its international expertise, using Defence's technology for targeted intracellular drug delivery to improve efficiency in targeting cancer cells, can make a significant contribution to the development of the next generation of radioimmunoconjugates."

    Evotec - Successful partnership

    In 2018, Evotec and Bristol Myers Squibb entered into a long-term partnership in the field of molecular glues. Bristol Myers Squibb is considered a leader in this field due to its unique compound library of Cereblon E3 Ligase Modulators. This strategic alliance aims to discover and develop a leading pipeline of Molecular Glue Degraders for various therapeutic indications. This will leverage all of Evotec's proprietary PanOmics and PanHunter platforms as well as AI/ML-based drug discovery and development capabilities. In May of last year, the collaboration was extended for an additional 8 years as the partnership is proving extremely productive in generating a promising pipeline of Molecular Glue Degraders.

    Evotec has significantly increased its efforts to develop promising compounds since the extension. The partnership continues to pursue discovering and developing a leading pipeline of novel Molecular Glue Degraders targeting high-value targets in oncology and beyond. Performance- and program-based successes now triggered USD 75 million in payments.

    Canadian bank RBC left its rating on Evotec at "outperform" with a price target of EUR 28. The drug discovery company's latest news on milestone payments represents a good start for the current year, and there is now upside potential for earnings estimates.

    Morphosys - Down to earth

    Shareholders of the biotech company from Planegg were only briefly in a celebratory mood when the share started a countermovement after the better-than-expected figures. Then the US investment bank JPMorgan came on the scene and found several points of criticism. For example, analyst James Gordon further lowered his Monjuvi forecasts for 2022. On the critical cancer drug candidate pelabresib, no groundbreaking news is expected until early 2024. The "underweight" rating was reiterated, as was the price target of EUR 11.

    Following the skeptical analyst opinions, the biotech stock lost more than 3% and is now trading again near the previous week's low of EUR 13.98. A break below the low at EUR 13.47 would pave the way to last year's low at EUR 11.80.

    Dr Jean-Paul Kress, CEO of Morphosys, takes a less negative view of the current situation. During the financial release, he commented, "In 2023, we will continue to prioritize the Phase III study for pelabresib in myelofibrosis in order to be able to publish topline results in early 2024 and to investigate the potential use of pelabresib in other myeloid diseases. We remain committed to developing and bringing to market novel therapies designed to be safer and more effective for cancer patients, and we look forward to the future."

    Despite better-than-expected numbers, Morphosys shares were again punished. Evotec's partnership with Bristol Myers Squibb flushes USD 75 million into the Hamburg-based company's coffers. Defence Therapeutics announced a far-reaching cooperation with the French state-owned group Orano.

    Conflict of interest

    Pursuant to §85 of the German Securities Trading Act (WpHG), we point out that Apaton Finance GmbH as well as partners, authors or employees of Apaton Finance GmbH (hereinafter referred to as "Relevant Persons") may hold shares or other financial instruments of the aforementioned companies in the future or may bet on rising or falling prices and thus a conflict of interest may arise in the future. The Relevant Persons reserve the right to buy or sell shares or other financial instruments of the Company at any time (hereinafter each a "Transaction"). Transactions may, under certain circumstances, influence the respective price of the shares or other financial instruments of the Company.

    In addition, Apaton Finance GmbH is active in the context of the preparation and publication of the reporting in paid contractual relationships.

    For this reason, there is a concrete conflict of interest.

    The above information on existing conflicts of interest applies to all types and forms of publication used by Apaton Finance GmbH for publications on companies.

    Risk notice

    Apaton Finance GmbH offers editors, agencies and companies the opportunity to publish commentaries, interviews, summaries, news and the like on These contents are exclusively for the information of the readers and do not represent any call to action or recommendations, neither explicitly nor implicitly they are to be understood as an assurance of possible price developments. The contents do not replace individual expert investment advice and do not constitute an offer to sell the discussed share(s) or other financial instruments, nor an invitation to buy or sell such.

    The content is expressly not a financial analysis, but a journalistic or advertising text. Readers or users who make investment decisions or carry out transactions on the basis of the information provided here do so entirely at their own risk. No contractual relationship is established between Apaton Finance GmbH and its readers or the users of its offers, as our information only refers to the company and not to the investment decision of the reader or user.

    The acquisition of financial instruments involves high risks, which can lead to the total loss of the invested capital. The information published by Apaton Finance GmbH and its authors is based on careful research. Nevertheless, no liability is assumed for financial losses or a content-related guarantee for the topicality, correctness, appropriateness and completeness of the content provided here. Please also note our Terms of use.

    Der Autor

    Stefan Feulner

    The native Franconian has more than 20 years of stock exchange experience and a broadly diversified network.
    He is passionate about analyzing a wide variety of business models and investigating new trends.

    About the author

    Related comments:

    Commented by Stefan Feulner on June 6th, 2023 | 07:15 CEST

    MediGene, BioNTech, BioNxt Solutions - New opportunities after the correction

    • Biotechnology
    • Pharma
    • Cancer

    Acquisitions by big pharma were increasingly expected in the biotechnology sector last year, but these largely failed to materialize. However, this trend could accelerate in the current year. On the one hand, pharmaceutical companies, such as the vaccine manufacturer Pfizer, have deep pockets and need new innovations for their product portfolio. On the other hand, second-tier stocks are attractive targets due to the strong correction.


    Commented by Juliane Zielonka on June 1st, 2023 | 09:30 CEST

    BioNxt Solutions, Bayer, Palantir - AI is dominating the market at breathtaking speed and ensuring high returns

    • Biotechnology
    • Pharma
    • AI

    Tech investors have suffered heavy losses over the past year. But tech in pharma and security in defence enables entirely new future scenarios whose precise developments are worth examining more closely. For example, gentler and more effective new ways that benefit patients are emerging in the drug delivery market. At the forefront is the Company BioNxt Solutions, which specializes in innovative transdermal patches whose active ingredients literally go under the skin. In Germany, the biotech company cooperates with a German pharmaceutical partner. New times are now dawning for Bayer as well. Under the new reign of CEO Bill Anderson, digital health seems to have finally found its positioning in the Consumer Health division. There, the Company is to cooperate with exciting start-ups that collect and analyze consumer data. When it comes to networking and interpreting data using AI, one company in particular stands out at the moment. Palantir is moving out to "dominate the entire market." How? Find out in the comments below.


    Commented by Fabian Lorenz on June 1st, 2023 | 08:45 CEST

    JinkoSolar, BioNTech and First Phosphate with important updates: This is what moves the shares

    • Mining
    • phosphate
    • photovoltaics
    • Biotechnology

    The energy transition is moving forward. In Germany, the traffic light government seems to have agreed on a new heating law. In the US, the agreement between Democrats and Republicans on the debt ceiling is a good sign for the industry because the promotion of environmentally friendly technologies depends on it. JinkoSolar and First Phosphate, among others, should benefit from this. Both companies have published important updates. There is also important news at BioNTech. However, these are not so positive. When will there be new impulses for the share?